Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary... par Ziegler, A, Achenbach, P, Berner, R, Casteels, K, Danne, T, Gündert, M, Hasford, J, Hoffmann, V, Kordonouri, O, Lange, K, Elding Larsson, H, Lundgren, M, Snape, M, Szypowska, A, Todd, J, Bonifacio, E, Gppad Study Group

Early-childhood body mass index and its association with the COVID-19 pandemic, containment measures and islet autoimmunity in children with increased risk for type 1 diabetes par Hummel, S, Rosenberger, S, von dem Berge, T, Besser, REJ, Casteels, K, Hommel, A, Kordonouri, O, Elding Larsson, H, Lundgren, M, Marcus, BA, Oltarzewski, M, Rochtus, A, Szypowska, A, Todd, JA, Weiss, A, Winkler, C, Bonifacio, E, Ziegler, A

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results par Winkler, C, Haupt, F, Heigermoser, M, Zapardiel-Gonzalo, J, Ohli, J, Faure, T, Kalideri, E, Hommel, A, Delivani, P, Berner, R, Kordonouri, O, Roloff, F, Von Dem Berge, T, Lange, K, Oltarzewski, M, Glab, R, Szypowska, A, Snape, M, Vatish, M, Todd, J, Larsson, H, Ramelius, A, Kördel, J, Casteels, K, Paulus, J, Ziegler, A, Bonifacio, E, GPPAD Study Group